Losartan, an angiotensin receptor blocker (ARB), is commonly used in the treatment of NS, and the AngiotensinII (AngII)–transient receptor potential ion channel 6 (TRPC6) axis has been reported to act on podocytes to regulate proteinuria in NS. This evidence concerns the gene AGT and Netherton syndrome.